NIH Plans Boozy Research Chat: Grants on Tap for 2026
Published Date: 1/21/2026
Notice
Summary
The National Institute on Alcohol Abuse and Alcoholism is holding important meetings on May 5 and possibly June 11, 2026, to review grant applications and discuss new research plans. These meetings affect researchers seeking funding and anyone interested in alcohol-related health studies. You can join in person or online, and some parts are private to protect sensitive info.
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
Grant Applications Will Be Reviewed
The National Advisory Council on Alcohol Abuse and Alcoholism will review and evaluate grant applications during a closed session on May 5, 2026 (11:00 a.m. to 12:30 p.m.), with a backup session June 11, 2026 (11:00 a.m. to 12:30 p.m.) if needed. If you are a researcher with a grant application, these are the dates when review work on applications will occur.
Public May Attend In Person or Online
The meeting on May 5, 2026 (and the possible June 11, 2026 session) is open to the public with attendance limited to space available, and can be accessed online via the NIH Videocast at https://videocast.nih.gov/. You can attend in person at 6700B Rockledge Drive, Bethesda, MD, or watch the videocast.
Closed Sessions Protect Confidential Information
Portions of the meetings (11:00 a.m. to 12:30 p.m.) will be closed under 5 U.S.C. 552b(c)(4) and (c)(6) because grant applications may contain trade secrets or personal information. This means applicants' confidential commercial material and personal data will not be discussed in public.
You Can File Written Comments
Any interested person may file written comments with the committee by sending a statement to the listed Contact Person (Philippe Marmillot, Ph.D.). Statements should include your name, address, telephone number, and, when applicable, business or professional affiliation.
Reasonable Accommodations Are Available
Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person in advance of the meeting. The notice provides the Contact Person’s phone and email for accommodation requests.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-01031, Certain Wireless Communication Devices and Components Thereof; Notice of Institution of Investigation
The U.S. International Trade Commission is starting an investigation because Active Wireless Technologies says some wireless devices and parts imported or sold in the U.S. are breaking their patents. If the claims are true, the Commission might block these products from entering the U.S. or being sold here. This could shake up the wireless market and affect companies selling these devices soon.
Next: 2026-01035, Sunshine Act Meetings
The National Credit Union Administration (NCUA) is holding an open meeting on January 22, 2026, to discuss updates on rules about dependent care and board member expenses, plus the budget for the Central Liquidity Facility. This affects credit union leaders and members by clarifying reimbursements and financial plans for the next year. No new costs or delays are expected, but it’s a key moment for transparency and planning.